Famotidine (oral)

Revision as of 16:25, 25 September 2007 by 58.0.247.205 (talk)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Famotidine (oral)
272px
Clinical data
[[Regulation of therapeutic goods |Template:Engvar data]]
Pregnancy
category
Routes of
administration
Oral, IV
ATC code
Legal status
Legal status
  • S3/S4 (Au), POM/OTC (UK),
    OTC/℞-only (U.S.)
Pharmacokinetic data
Bioavailability20–66%
Protein binding10–28%
Metabolismhepatic-less than 30%
Elimination half-life2.5-4 hours (clinical half-life 8-12 hours)
ExcretionPrincipally excreted unchanged in urine
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC8H15N7O2S3
Molar mass337.449 g/mol

Famotidine (INN) (IPA: [fəˈmɒtɪdin]) is a histamine H2-receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). It is commonly marketed by Merck under the trade names Pepcidine and Pepcid.

Clinical use

Main article: H2-receptor antagonist

Certain preparations of famotidine are available over the counter (OTC) in various countries. In the United States, preparations of 10 mg and 20 mg tablets, sometimes in combination with a more traditional antacid, are available OTC. Larger doses still require a prescription.

Famotidine is given to surgery patients before operations to prevent post-operation nausea.

History and development

Famotidine was developed by Merck & Co.. The imidazole-ring of cimetidine was replaced with a 2-guanidinothiazole ring. Famotidine proved to be 30 times more active than cimetidine.

It was first marketed in 1985. Pepcid RPD orally-disintegrating tablets (that are not swallowed) was released in 1999. Generic preparations became available in 2001, e.g. Fluxid (Schwarz) or Quamatel (Gedeon Richter Ltd.). In the United States, a product called Pepcid Complete is available that combines famotidine with an antacid in a chewable tablet to ameliorate the relatively slow onset of effects. In the UK, this product is known as Pepcidtwo.

nl:Famotidine th:ฟาโมติดีน


Linked-in.jpg